-+ 0.00%
-+ 0.00%
-+ 0.00%

Johnson & Johnson: The Duplex-AD phase 2b proof-of-concept study for the treatment of moderate to severe atopic dermatitis did not meet efficacy goals.

Zhitongcaijing·12/26/2025 13:33:02
Listen to the news
Johnson & Johnson: The Duplex-AD phase 2b proof-of-concept study for the treatment of moderate to severe atopic dermatitis did not meet efficacy goals.